These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 10325362

  • 21. In vitro activity of linezolid (U-100766) against Haemophilus influenzae measured by three different susceptibility testing methods.
    Biedenbach DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2001 Jan; 39(1):49-53. PubMed ID: 11173191
    [Abstract] [Full Text] [Related]

  • 22. Changing antimicrobial susceptibility patterns among Streptococcus pneumoniae and Haemophilus influenzae from Brazil: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Castanheira M, Gales AC, Pignatari AC, Jones RN, Sader HS.
    Microb Drug Resist; 2006 Jan; 12(2):91-8. PubMed ID: 16922623
    [Abstract] [Full Text] [Related]

  • 23. Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: the BSAC Respiratory Resistance Surveillance Programme.
    Reynolds R, Shackcloth J, Felmingham D, MacGowan A, BSAC Extended Working Party on Respiratory Resistance Surveillance.
    J Antimicrob Chemother; 2003 Dec; 52(6):925-30. PubMed ID: 14585864
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).
    Jones RN, Biedenbach DJ.
    Diagn Microbiol Infect Dis; 2003 Apr; 45(4):273-8. PubMed ID: 12729999
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and moraxella catarrhalis by MIC determination and time-kill assay.
    Pankuch GA, Hoellman DB, Lin G, Bajaksouzian S, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1998 Nov; 42(11):3032-4. PubMed ID: 9797250
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Interpretive criteria and quality control guidelines for lomefloxacin and meropenem in susceptibility tests of Haemophilus influenzae using Haemophilus test medium.
    Pfaller MA, Jones RN, Washington JA, Koontz FP, Gerlach EH, Erwin ME.
    Diagn Microbiol Infect Dis; 1992 Feb; 15(2):145-50. PubMed ID: 1315231
    [Abstract] [Full Text] [Related]

  • 31. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000.
    Koeth LM, Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Appelbaum PC.
    Int J Antimicrob Agents; 2002 Jan; 19(1):33-7. PubMed ID: 11814765
    [Abstract] [Full Text] [Related]

  • 32. Susceptibility trends of haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program.
    Johnson DM, Sader HS, Fritsche TR, Biedenbach DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2003 Sep; 47(1):373-6. PubMed ID: 12967753
    [Abstract] [Full Text] [Related]

  • 33. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
    Morrissey I, Robbins M, Viljoen L, Brown DF.
    J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
    [Abstract] [Full Text] [Related]

  • 34. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN, Ballow CH, Schentag JJ, Johnson DM, Deinhart JA.
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study.
    Jones ME, Staples AM, Critchley I, Thornsberry C, Heinze P, Engler HD, Sahm DF.
    Diagn Microbiol Infect Dis; 2000 Jul; 37(3):203-11. PubMed ID: 10904194
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae.
    Hedlin P, Blondeau JM.
    Eye Contact Lens; 2007 May; 33(3):161-4. PubMed ID: 17502752
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.